Genentech

#Breaking: Pivotal Phase III results in previously treated KRAS G12C-mutated non-small cell lung cancer presented as an ESMO late-breaker and simultaneously published in the @NEJM. Learn more about our commitment to advancing innovation in #LungCancer: gene.com/media/press-re…

#Breaking: At @ASNKidney #KidneyWk, we presented positive interim Phase III results of our investigational treatment for IgA nephropathy (IgAN), a chronic and progressive kidney disease.

Learn more: gene.com/media/press-re…

#Breaking: At the joint ACTRIMS-ECTRIMS meeting this week, we're presenting new data in MS and MOGAD. We remain committed to developing innovative medicines for patients with neurological diseases. #MSToronto2026

Learn more: gene.com/media/press-re…

#Breaking: At #ESMO26, we are presenting new data across our broad oncology portfolio, including lung, breast and other cancers, highlighting our continued commitment to advancing innovation for people living with cancer. Learn more: gene.com/media/press-re…

#Breaking: The @US_FDA has approved our treatment for adults with thyroid eye disease (TED), providing patients with a new option to help address this complex disease. Read more here:  gene.com/media/press-re…